Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Introduction to Hemostasis01:05

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Coagulation01:09

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reducing mortality, improving outcomes, and establishing equity for women with classical haematological disease: a Lancet Haematology Commission.

The Lancet. Haematology·2026
Same author

Real-time sensing-integrated organoid-on-a-chip platforms: Technological progress and emerging biomedical applications.

Bioactive materials·2026
Same author

Evaluation of Red Blood Cell Biomechanics in the Setting of Cancer-Associated Anemia and Chemotherapy.

Microcirculation (New York, N.Y. : 1994)·2026
Same author

DIC in pregnancy: lessons from an international registry of the International Society for Thrombosis and Hemostasis: Communication from the SSC of the ISTH.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Red Blood Cells in Hemostasis and Thrombosis: Mechanisms, Interactions, and Clinical Implications.

Seminars in thrombosis and hemostasis·2026
Same author

Decomposing cultural differences in behavior toward members of different social groups.

PNAS nexus·2026

Related Experiment Video

Updated: Jun 3, 2026

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro
10:25

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro

Published on: March 19, 2016

Designing the Future of Hemostasis.

Thomas D Kazmirchuk1,2, Jiashu Wang2, Janice Corbette2

  • 1Queen's University, Department of Biomedical and Molecular Sciences, Canada, Kingston.

Seminars in Thrombosis and Hemostasis
|June 1, 2026
PubMed
Summary

New peptide therapeutics designed using artificial intelligence offer precise treatments for bleeding disorders by targeting specific platelet-protein interactions, improving upon traditional therapies.

More Related Videos

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Related Experiment Videos

Last Updated: Jun 3, 2026

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro
10:25

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro

Published on: March 19, 2016

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Area of Science:

  • Hematology
  • Computational Biology
  • Drug Design

Background:

  • Bleeding disorders stem from complex platelet-protein interactions, challenging traditional treatments.
  • Primary hemostasis relies on von Willebrand factor (VWF) and platelet receptors GPIbα and αIIbβ3.
  • Existing therapies face limitations in availability, cost, immunogenicity, and precision.

Purpose of the Study:

  • To review advanced peptide drug design strategies for hematologic therapeutics.
  • To highlight the potential of AI and computational biology in developing targeted peptide therapies.
  • To introduce G14, an AI-designed peptide for treating specific bleeding disorders.

Main Methods:

  • Structure-based modeling and small motif (SM)-based design for peptide engineering.
  • Utilizing artificial intelligence (AI) for designing peptides targeting protein-protein interactions (PPIs).
  • Developing G14 to selectively disrupt the GPIbα-VWF interaction in platelet disorders.

Main Results:

  • Peptide design strategies enable creation of stable peptides targeting disease-specific PPIs.
  • G14 selectively inhibits enhanced patient-derived platelet aggregation and VWF binding.
  • AI-driven peptide design shows promise for rapid, scalable, and personalized bleeding disorder therapies.

Conclusions:

  • Intelligently designed peptides represent a new frontier in precision medicine for bleeding disorders.
  • Combining systems biology, structural modeling, and AI accelerates therapeutic development.
  • Peptide-based therapies offer a more precise and potentially scalable approach to hemostasis and thrombosis management.